{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T23:53:06Z","timestamp":1792799586696,"version":"4.5.0"},"reference-count":64,"publisher":"American Society for Clinical Investigation","issue":"22","funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["U54CA198999"],"award-info":[{"award-number":["U54CA198999"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["U19AI109784"],"award-info":[{"award-number":["U19AI109784"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["T32-AI007151"],"award-info":[{"award-number":["T32-AI007151"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["5T32-AI007273"],"award-info":[{"award-number":["5T32-AI007273"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100005562","name":"North Carolina Biotechnology Center","doi-asserted-by":"crossref","award":["2018-BIG-6504"],"award-info":[{"award-number":["2018-BIG-6504"]}],"id":[{"id":"10.13039\/100005562","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["P30-CA016086-40"],"award-info":[{"award-number":["P30-CA016086-40"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Lineberger Comprehensive Cancer Center, University of North Carolina","award":["2017-T2-12"],"award-info":[{"award-number":["2017-T2-12"]}],"id":[{"id":"https:\/\/ror.org\/043ehm030","id-type":"ROR","asserted-by":"crossref"}]},{"name":"National Cancer Institute","award":["F99CA223019"],"award-info":[{"award-number":["F99CA223019"]}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["T32-AI07273"],"award-info":[{"award-number":["T32-AI07273"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["T32-HL007106"],"award-info":[{"award-number":["T32-HL007106"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,11,15]]},"abstract":"<jats:p>\n                    Triple-negative breast cancer (TNBC) has few therapeutic options, and alternative approaches are urgently needed. Stimulator of IFN genes (STING) is becoming an exciting target for therapeutic adjuvants. However, STING resides inside the cell, and the intracellular delivery of CDNs, such as cGAMP, is required for the optimal activation of STING. We show that liposomal nanoparticle-delivered cGAMP (cGAMP-NP) activates STING more effectively than soluble cGAMP. These particles induce innate and adaptive host immune responses to preexisting tumors in both orthotopic and genetically engineered models of basal-like TNBC. cGAMP-NPs also reduce melanoma tumor load, with limited responsivity to anti\u2013PD-L1. Within the tumor microenvironment, cGAMP-NPs direct both mouse and human macrophages (M), reprograming from protumorigenic M2-like phenotype toward M1-like phenotype; enhance MHC and costimulatory molecule expression; reduce M2 biomarkers; increase IFN-\u03b3\u2013producing T cells; augment tumor apoptosis; and increase CD4\n                    <jats:sup>+<\/jats:sup>\n                    and CD8\n                    <jats:sup>+<\/jats:sup>\n                    T cell infiltration. Activated T cells are required for tumor suppression, as their depletion reduces antitumor activity. Importantly, cGAMP-NPs prevent the formation of secondary tumors, and a single dose is sufficient to inhibit TNBC. These data suggest that a minimal system comprised of cGAMP-NP alone is sufficient to modulate the tumor microenvironment to effectively control PD-L1\u2013insensitive TNBC.\n                  <\/jats:p>","DOI":"10.1172\/jci.insight.120638","type":"journal-article","created":{"date-parts":[[2018,11,14]],"date-time":"2018-11-14T11:01:38Z","timestamp":1542193298000},"source":"Crossref","is-referenced-by-count":243,"title":["A nanoparticle-incorporated STING activator enhances antitumor immunity in PD-L1\u2013insensitive models of triple-negative breast cancer"],"prefix":"10.1172","volume":"3","author":[{"given":"Ning","family":"Cheng","sequence":"first","affiliation":[{"name":"Oral and Craniofacial Biomedicine Program, School of Dentistry,"},{"name":"Lineberger Comprehensive Cancer Center,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebekah","family":"Watkins-Schulz","sequence":"additional","affiliation":[{"name":"Lineberger Comprehensive Cancer Center,"},{"name":"Curriculum of Genetics and Molecular Biology,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert D.","family":"Junkins","sequence":"additional","affiliation":[{"name":"Lineberger Comprehensive Cancer Center,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cl\u00e9ment N.","family":"David","sequence":"additional","affiliation":[{"name":"Lineberger Comprehensive Cancer Center,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandon M.","family":"Johnson","sequence":"additional","affiliation":[{"name":"Lineberger Comprehensive Cancer Center,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie A.","family":"Montgomery","sequence":"additional","affiliation":[{"name":"Lineberger Comprehensive Cancer Center,"},{"name":"Department of Pathology and Laboratory Medicine,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin J.","family":"Peine","sequence":"additional","affiliation":[{"name":"Eshelman School of Pharmacy, Division of Pharmacoengineering and Molecular Pharmaceutics,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David B.","family":"Darr","sequence":"additional","affiliation":[{"name":"Lineberger Comprehensive Cancer Center,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Yuan","sequence":"additional","affiliation":[{"name":"Department of Radiology,"},{"name":"Biomedical Imaging Research Center,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen P.","family":"McKinnon","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Immunology,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Liu","sequence":"additional","affiliation":[{"name":"Eshelman School of Pharmacy, Division of Pharmacoengineering and Molecular Pharmaceutics,"},{"name":"University of North Carolina\/North Carolina State University Joint Department of Biomedical Engineering,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Miao","sequence":"additional","affiliation":[{"name":"Eshelman School of Pharmacy, Division of Pharmacoengineering and Molecular Pharmaceutics,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leaf","family":"Huang","sequence":"additional","affiliation":[{"name":"Lineberger Comprehensive Cancer Center,"},{"name":"Eshelman School of Pharmacy, Division of Pharmacoengineering and Molecular Pharmaceutics,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric M.","family":"Bachelder","sequence":"additional","affiliation":[{"name":"Eshelman School of Pharmacy, Division of Pharmacoengineering and Molecular Pharmaceutics,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristy M.","family":"Ainslie","sequence":"additional","affiliation":[{"name":"Eshelman School of Pharmacy, Division of Pharmacoengineering and Molecular Pharmaceutics,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny P-Y","family":"Ting","sequence":"additional","affiliation":[{"name":"Oral and Craniofacial Biomedicine Program, School of Dentistry,"},{"name":"Lineberger Comprehensive Cancer Center,"},{"name":"Curriculum of Genetics and Molecular Biology,"},{"name":"Department of Microbiology and Immunology,"},{"name":"Department of Genetics,"},{"name":"Institute for Inflammatory Diseases, and"},{"name":"Center for Translational Immunology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"232","published-online":{"date-parts":[[2018,11,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1503093"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504030"},{"issue":"6","key":"B3","doi-asserted-by":"crossref","DOI":"10.1038\/nrclinonc.2016.65","article-title":"The future of cancer treatment: immunomodulation, CARs and combination immunotherapy","volume":"13","author":"Khalil","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/nature14011"},{"key":"B5","doi-asserted-by":"crossref","first-page":"abstr PD1","DOI":"10.1158\/1538-7445.AM2015-2859","article-title":"Inhibition of PD-L1 by MPDL3280A leads to clinical activity in patients with metastatic triple-negative breast cancer","volume":"75","author":"Emens","year":"2015","journal-title":"Cancer Res"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1210\/me.2010-0164"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.64.8931"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1126\/science.1252510"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2013.02.013"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-09-0280"},{"key":"B11","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2017.00828","article-title":"Reprogramming of tumor-associated macrophages with anticancer therapies: radiotherapy versus chemo- and immunotherapies","volume":"8","author":"Genard","year":"2017","journal-title":"Front Immunol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-1362"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/nnano.2017.52"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2015.04.031"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/nri3133"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1126\/science.1232458"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1621363114"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/nrc.2016.108"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2015.08.068"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/nrd2110"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2015.02.006"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/ni.1937"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1402066"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1203280"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1172\/JCI69804"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2014.06.010"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2011.12.001"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2249.2011.04515.x"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2016.04.084"},{"key":"B30","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2014.00614","article-title":"Molecular mechanisms that influence the macrophage m1-m2 polarization balance","volume":"5","author":"Wang","year":"2014","journal-title":"Front Immunol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1200690"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1038\/70932"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1084\/jem.192.7.1027"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.immunol.26.021607.090331"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1038\/nature19330"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1172\/JCI80011"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.30258"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2017.43"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-018-0316-z"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-0493"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.SABCS-09-2166"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1038\/cmi.2014.83"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1002\/eji.201344304"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-60327-360-2_13"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.91.23.11236"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1103849"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1038\/nature21349"},{"issue":"1","key":"B48","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","article-title":"Chimeric antigen receptor T-cell therapy - assessment and management of toxicities","volume":"15","author":"Neelapu","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv623"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1038\/nature07317"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2008.09.003"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2014.10.017"},{"key":"B53","article-title":"Antitumor activity of cGAMP via stimulation of cGAS-cGAMP-STING-IRF3 mediated innate immune response","volume":"6","author":"Li","year":"2016","journal-title":"Sci Rep"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.2910220307"},{"issue":"17","key":"B55","first-page":"5299","article-title":"Stat1-dependent induction of tumor necrosis factor-related apoptosis-inducing ligand and the cell-surface death signaling pathway by interferon beta in human cancer cells","volume":"63","author":"Choi","year":"2003","journal-title":"Cancer Res"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.immunol.22.012703.104803"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2006.01.007"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1038\/nrc1256"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2015.02.004"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2010.03.014"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1038\/ni.3117"},{"issue":"2","key":"B62","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.nano.2017.10.013","article-title":"Biodegradable STING agonist nanoparticles for enhanced cancer immunotherapy","volume":"14","author":"Wilson","year":"2018","journal-title":"Nanomedicine"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.3109\/08982100902838682"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-60327-360-2_25"}],"container-title":["JCI Insight"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/insight.jci.org\/articles\/view\/120638\/files\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T12:38:59Z","timestamp":1779194339000},"score":1,"resource":{"primary":{"URL":"https:\/\/insight.jci.org\/articles\/view\/120638"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,15]]},"references-count":64,"journal-issue":{"issue":"22","published-online":{"date-parts":[[2018,11,15]]},"published-print":{"date-parts":[[2018,11,15]]}},"alternative-id":["10.1172\/jci.insight.120638"],"URL":"https:\/\/doi.org\/10.1172\/jci.insight.120638","relation":{},"ISSN":["2379-3708"],"issn-type":[{"value":"2379-3708","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,15]]},"article-number":"e120638"}}